Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Occult Gynecologic Cancer in Hysterectomy or Myomectomy

Obstet Gynecol; ePub 2018 Mar 8; Desai, et al

Among women undergoing hysterectomies and varied by age and surgical route, prevalence of occult corpus uteri, cervical, and ovarian malignancy was 1.44%, 0.60%, and 0.19%. The secondary analysis of data from the 2014-2015 American College of Surgeons National Surgical Quality Improvement Program included 24,076 women undergoing hysterectomy and 2,368 women undergoing myomectomy. The primary outcome measure was pathology-confirmed malignancy in the corpus uteri, cervix uteri, and ovary. Researchers found:

  • Malignancy of the corpus uteri was found in 1.44% of the women undergoing hysterectomy.
  • The prevalence varied considerably across surgical routes with the rate being 0.23% in laparoscopic supracervical hysterectomy and 1.89% in total laparoscopic or laparoscopic-assisted vaginal hysterectomy.
  • Older women were significantly more like to have preoperatively undetected malignancy of the corpus uteri.


Desai VB, Wright JD, Schwartz PE, et al. Occult gynecologic cancer in women undergoing hysterectomy or myomectomy for benign indications. [Published online ahead of print March 8, 2018]. Obstet Gynecol. doi:10.1097/AOG.0000000000002521.